文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

高疾病严重程度ICU患者的泮托拉唑预防:SUP-ICU安慰剂对照试验的事后分析

Pantoprazole prophylaxis in ICU patients with high severity of disease: a post hoc analysis of the placebo-controlled SUP-ICU trial.
PubMed 文献 · Intensive Care Med · 2019-03-12
一句话结论SUP-ICU事后分析显示,基线SAPS II>53的ICU患者使用泮托拉唑较安慰剂90天死亡率更高(RR 1.13,95%CI 1.00-1.29),但部分可能由SAPS II数据缺失解释,需进一步研究。

该研究为SUP-ICU试验的事后分析,纳入基线SAPS II>53的急性入院成人患者1140例,比较泮托拉唑与安慰剂对90天死亡率的影响。泮托拉唑组90天死亡272/579例(47%),安慰剂组229/558例(41%),相对风险1.13(95%CI 1.00-1.29)。校正风险因素及符合方案集分析支持该结果;两项补充分析中相对风险分别为1.08(95%CI 0.96-1.22)和1.10(95%CI 0.97-1.25)。次要结局中无生命支持存活天数亦观察到类似差异,其他次要结局无差异。作者认为部分差异可能由SAPS II数据缺失解释,需进一步研究以得出确切结论。

要点

  • 在SUP-ICU试验基线SAPS II>53的亚组中,泮托拉唑组90天死亡272/579例(47%)vs 安慰剂组229/558例(41%),相对风险1.13(95%CI 1.00-1.29)。
  • 校正风险因素及符合方案集分析支持上述结果;两项补充分析相对风险分别为1.08(95%CI 0.96-1.22)和1.10(95%CI 0.97-1.25)。
  • 次要结局无生命支持存活天数亦观察到泮托拉唑组少于安慰剂组,其他次要结局无差异。
  • 作者认为部分差异可能由SAPS II数据缺失解释,需进一步研究以得出确切结论。
  • 该分析为SUP-ICU试验的事后分析,纳入基线SAPS II>53的急性入院成人患者1140例。

适用人群与场景

  • SUP-ICU试验中急性入院、有胃肠道出血风险的成人患者,基线SAPS II>53且SAPS II数据完整者1140例纳入本分析。

诊断标准与关键阈值

  • 基线简化急性生理评分II(SAPS II)>53。

研究设计与关键结果

  • 研究类型为SUP-ICU安慰剂对照试验的事后分析,纳入基线SAPS II>53的急性入院成人患者1140例,比较泮托拉唑与安慰剂。
  • 主要终点90天死亡率:泮托拉唑组272/579例(47%)vs 安慰剂组229/558例(41%),相对风险1.13(95%CI 1.00-1.29)。
  • 校正风险因素及符合方案集分析支持主要结果;两项补充分析相对风险分别为1.08(95%CI 0.96-1.22)和1.10(95%CI 0.97-1.25)。
  • 次要结局无生命支持存活天数亦观察到泮托拉唑组少于安慰剂组,其他次要结局两组间无差异。

证据类型、等级与局限

  • 证据类型:安慰剂对照试验(SUP-ICU)的事后分析。
  • 局限:部分差异可能由SAPS II数据缺失解释;需进一步研究以得出确切结论。

对床旁实践的改变

  • 作者认为,在基线SAPS II>53的ICU患者中观察到泮托拉唑组90天死亡率更高、无生命支持存活天数更少,但部分可能由SAPS II数据缺失解释,需进一步研究以得出确切结论。

指南或共识出处

  • SUP-ICU试验(Stress Ulcer Prophylaxis in Intensive Care Unit),ClinicalTrials.gov No. NCT02467621。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: In the subgroup of patients with Simplified Acute Physiology Score (SAPS) II > 53 in the Stress Ulcer Prophylaxis in Intensive Care Unit (SUP-ICU) trial, there was interaction (P = 0.049) suggesting increased mortality in patients allocated to pantoprazole as compared with placebo. We aimed to explore this further.

METHODS: The SUP-ICU trial allocated acutely admitted adults at risk of gastrointestinal bleeding to pantoprazole vs placebo. In this post hoc study, we repeated all the preplanned analyses of SUP-ICU in patients with baseline SAPS II > 53.

RESULTS: A total of 1140 patients had a complete SAPS II > 53 and were included. At 90 days, 272/579 patients (47%) assigned to pantoprazole had died, as compared with 229/558 patients (41%) assigned to placebo [relative risk 1.13; 95% confidence interval (CI) 1.00-1.29]. This was supported by sensitivity analyses adjusted for risk factors and those in the per-protocol population. When accounting for patients with incomplete SAPS II in two additional analyses, the relative risk was 1.08; 95% CI 0.96-1.22 and 1.10; 95% CI 0.97-1.25. This was also observed for the secondary outcome days alive without life support. There were no differences between the intervention groups in the other secondary outcomes.

CONCLUSIONS: In this post hoc analysis of patients with high disease severity included in the SUP-ICU trial, we observed higher 90-day mortality and fewer days alive without life support with pantoprazole vs placebo. Some of this may have been explained by missing SAPS II data, but further research is needed to draw firm conclusions. CLINICALTRIALS.GOV: ClinicalTrials.gov No. NCT02467621.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Marker S, Perner A, Wetterslev J, et al. Pantoprazole prophylaxis in ICU patients with high severity of disease: a post hoc analysis of the placebo-controlled SUP-ICU trial. Intensive Care Med. 2019. PMID: 30863936. doi:10.1007/s00134-019-05589-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。